Summary
KEYNOTE-361 was a phase 3 randomised controlled trial evaluating pembrolizumab monotherapy and pembrolizumab plus chemotherapy as first-line treatments for advanced urothelial carcinoma compared to chemotherapy alone. The trial enrolled patients internationally and measured survival outcomes, response rates, and treatment toxicity. As this is a cancer immunotherapy study, findings are relevant to oncological practice rather than agricultural or nutritional systems.
UK applicability
This trial's findings would inform National Health Service oncology guidelines and clinical practice for urothelial carcinoma treatment. The results are directly applicable to UK cancer care pathways and treatment decision-making in urology and medical oncology.
Key measures
Overall survival, progression-free survival, objective response rate, adverse events, quality of life metrics
Outcomes reported
The study compared efficacy and safety of pembrolizumab monotherapy or combined with chemotherapy versus chemotherapy alone as first-line treatment for advanced urothelial carcinoma. Primary outcomes likely included overall survival, progression-free survival, and objective response rates.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.